Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the start of... (Source: - Clinical Trials)
Source: - Clinical Trials - December 12, 2017 Category: Pharmaceuticals Source Type: clinical trials

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
Condition:   Fibrodysplasia Ossificans Progressiva Interventions:   Drug: REGN2477;   Drug: Matching placebo Sponsor:   Regeneron Pharmaceuticals Not yet recruiting - verified June 2017 (Source:
Source: - June 13, 2017 Category: Research Source Type: clinical trials

The Fibrodysplasia Ossificans Progressiva (FOP) Connection Registry
Condition:   Fibrodysplasia Ossificans Progressiva (FOP)Intervention:   Sponsor:   The International FOP AssociationRecruiting - verified March 2016 (Source:
Source: - March 6, 2016 Category: Research Source Type: clinical trials

In-Home Evaluation of Episodic Administration of Palovarotene in Fibrodysplasia Ossificans Progressiva (FOP) Subjects
Condition:   Fibrodysplasia Ossificans ProgressivaIntervention:   Drug: PalovaroteneSponsor:   Clementia Pharmaceuticals Inc.Not yet recruiting - verified August 2015 (Source:
Source: - August 6, 2015 Category: Research Source Type: clinical trials

A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP)
Condition:   Fibrodysplasia Ossificans ProgressivaIntervention:   Sponsor:   Clementia Pharmaceuticals Inc.Recruiting - verified December 2014 (Source:
Source: - December 8, 2014 Category: Research Source Type: clinical trials